Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-ICAM-1pep PET/CT for Tumor Response to Radiotherapy
NCT04596670Phase 1Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-ICAM-1pep in cancer (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Standardized Uptake Values (SUVs) of 68Ga-ICAM-1pep at baseline and Changes in Standardized Uptake Values (SUVs) of 68Ga-ICAM-1pep during radiotherapy. Started Sep 2024; status: recruiting.
02
Drugs
68Ga-ICAM-1pep
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04596670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04596670.